Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The companies will work to discover, develop and commercialize novel therapies that modulate G protein-coupled receptor (GPCR) targets that AbbVie selects.
ring to push boundaries, upend limitations, and put mankind on the moon. In a strategic new alignment, Van Heron Labs, a startup formed in Houston, will begin working alongside Huntsville’s Foresight Biosciences to continue the tradition.
The Brisbane, California-based company announced its plans to separate the two units and treat them as individual operations with individual managers.
Enterome SA, based in Paris and Cambridge, Massachusetts, announced a new financing totaling $52.6 million (€46.3 million). This was a Series E round.
COVID-19-related testimonies will continue in Congress today, with representatives from the Biotechnology Innovation Organization (BIO) expected to address the current pandemic as well as key priorities that will need to be in place in order to effectively respond to the next global viral threat.
Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs.
Speaking before Congress on Tuesday, Dr. Anthony Fauci urged people to adopt strategies that involve wearing a mask in public, maintaining social distance and avoiding large gatherings of people.
Baltimore-based AsclepiX Therapeutics closed a $35 million Series A financing.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
Artificial intelligence (AI) is amplifying the pace of drug development, allowing developers to attack otherwise intractable problems and achieve results in weeks. Previously, results may have been impossible within any time frame.